Bioceres Crop Solutions Corp.

Today's call will be Federico Trucco, ESER's Chief Executive Officer, and Enrique Lopez-Lecue, our Chief Financial Officer. Both will be available for the Q&A session. Before we proceed, I would like to make the following self-help statement. Today's call will contain forward-looking statements and I refer you to the forward-looking statement section of today's earnings release and presentation. As well, in our recent findings with the SEC, we assume no obligation to update or revise any forward-looking statements to reflect new or change events or circumstances. Also, please note that for comparison purposes and a better understanding of our company's underlying performance, in addition to discussing the reported results during our presentation today, we will discuss comparable results, which exclude the impact of hyperinflation accounting in Argentina. Additional information in connection with the application of the rule IAS 29 can be found in our earnings report. Finally, this conference call is being webcast. The webcast link is available in the investor relations section of diocerescrops.com. At this time, I would like to turn the call over to our CEO, Federico Trucco.

Thanks, Max, and thank you all for joining us today. Please turn to slide two for a brief overview of the business and financial highlights we will discuss in today's call. As we have done in past calls, we will discuss the progress in the rollout of HB4 wheat and soy from a number of different perspectives, including the seed multiplication perspective, grower onboarding and validation of our value proposition, regulatory activities, sustainability framework, and consumer engagement. We will also discuss the realignment of non-core GLA assets in exchange for a 6% ownership interest in Mulex Science, a molecular farming company pursuing a hybrid concept between plant and cell-based technologies for the production of animal-free food solutions. From a baseline business perspective, we will discuss some reorganizational activities implemented after our second quarter results that are starting to bear fruit, most significantly in our crop nutrition segment with a four times increase in microbeaded fertilizer sales year over year, resulting in a 35% total comparable revenue growth for the quarter. This top-line growth, combined with operating leverage, enabled the company to deliver improved adjusted EBITDA and margin expansion during the reported period, positioning our financial profile into the double-digit growth trajectory on an LTM basis. Now, let us discuss these highlights in greater depth. Please turn to slide three for an update on the upcoming HB4 wheat production season. The strong performance of HB4 wheat varieties observed during the last crop cycle and reported in our second quarter's earnings call has created an excellent pre-season momentum with contracts already in place for over 60,000 hectares, our baseline target prior to Brazil import approval. We have collected and will continue to collect indications for additional hectares until the end of May, but we will only turn these indications into contracts if a Brazil clearance is obtained in due time. Last season, HB4 wheat outyielded conventional varieties by 13.5% across all environments and locations, and up to 42% in low-yielding environments. As we look forward to the planting season, we currently have 200 growers engaged across 550 locations with a near 100% customer repeat rate, with past participants more than tripling the number of hectares planted last year. Clearly, this strong adoption validates the HB4 value proposition. As of today, contributed goods for an HB4 wheat hectare average approximately $100, with a gross margin above our company-wide average. In terms of financial reporting, the value of these contributed goods will be recognized as revenues once the realized inventories are sold as seed or grain and no longer contributed into seed multiplication agreements. For the time being, this has a financial benefit for the company as the corresponding gross profit from contributed goods implies that less cash is required for the HB4 inventory build-up process. Turning to slide four, you can see we have made substantial progress leveraging technology to interact with prospective growers and manage their HB4 program onboarding. We have onboarded almost 50% of our customers via our Generation HB4 digital platform, fully automating the commercial interaction, credit scoring, contract execution, and input logistics. In terms of functionality, on the left side of the slide, you can see a mobile-like app that makes sign-up, data entry, and navigation all seamless, while encompassed in a secure environment with biometric entry parameters. Growers can sign up for the program by geopositioning fields and receiving an automated seed recommendation and inputs budgeting in only six simple steps. As you look to the right, you can see a comprehensive dashboard that manages the entire experience with an optional communication tool utilizing an AI chat box. On this dashboard, you can manage orders, invoicing, billing, traceability, stewardship, and customized APIs. The platform is still in a beta testing stage, and we hope that input from the current cycle will allow us to perfect it further and make it the prevalent grower acquisition and relationship management channel in coming cycles. Please turn to slide five for an update on HP4 SOIP. Of the close to 23,000 hectares planted with seven different HB4 soy varieties, we have already harvested slightly over 13,000 hectares with yields averaging 1.8 tons on a per hectare basis. Bear in mind that we position current varieties in HB4 targeted regions with yields normally below the 2.5 tons per hectare. We expect harvest to be almost completed before the end of the month. Resulting inventories from the current and next soybean cycles and from the upcoming wheat cycle should put us in an excellent position for a meaningful launch once key regulatory clearances are achieved. Turning to slide six. As we look to our HB4 regulatory progress, during the fiscal third quarter, our team made a formal submission for HB4 wheat production approval to the USDA in the United States. Although this is not an immediate opportunity for us, certain regions of the U.S. represent attractive medium-term markets. Its progress in Latin America continues to be favorable. You will see similar submissions to other medium-term geographies in quarters to come. No additional information has been requested during the quarter by Chinese regulatory authorities regarding HB4 soil, nor by Brazil's Etenerio regarding their ongoing evaluation of HB4 wheat. We believe both regulators should be able to resolve approval requests in their upcoming their findings as they are informed to us. Now, let's review our new corporate ESG initiatives. Turning to slide seven, our value proposition has always form of improved yields, management practices, and other efficiencies to further decarbonize our customers' production processes while regenerating agricultural ecosystems. Even though our HPCOP program integrates several good farming practices such as crop rotation, note of farming, biological nutrition and protection, among others, aligned with regenerative agriculture, we decided to initially focus our sustainability framework on the HB4 technology alone. HB4 seed varieties increased yields by 10 to 20% under drought conditions, resulting in up to 7% additional CO2 savings on average when compared to non-HB4 varieties. we have engaged with BGO 80s, a global leader in ESG assessment, to produce an independent opinion on our sustainability framework. BGO 80s is of the opinion that the selected KPI stands of CO2 equivalent cumulative savings in soybean wheat primary production systems results relevant, coherent, and material from an environmental standpoint. as well as it reflects relevant sustainability challenges for the activities of the company related to the agricultural sector, mainly United Nations Sustainable Development Goals 2 and 13, namely Zero Hunger and Climate Action. Moreover, the framework sets the aesthetics to achieve ambitious goals of fixing 156,000 tons of CO2 equivalents by 2025, as HB4 soy and wheat rollout projections are next. Please turn to slide eight. Subsequent to the closing of the fiscal third quarter and on the heels of validating HB4 sustainability framework, we entered into our first agreement with a consumer brand, Havana, to roll out food products manufactured with HB4 wheat flour. The new agreement will give Havana customers in Brazil and Argentina the option to choose food products with a significantly reduced carbon footprint and other environmentally positive externalities that help fight climate change and preserve native ecosystems. Importantly, The farm-to-fork identity preserve process structure under the ongoing Generation HP4 program will enable Havana Bioservice products to include field-specific information, climate facts, and other key data of potential interest to consumers, all secured on blockchain technology. Founded in 1947, Havana has become a leading player in the high-end coffee shop segment in South America. operating over 300 stores in premium locations across Argentina, Brazil, Chile, and Peru, as well as Spain and the United States. Turning now to slide 9, towards the end of the fiscal third quarter, we realigned non-core GLA assets in exchange for a 6% ownership interest in Molex Science, a molecular farming company pursuing a hybrid concept between plant and cell-based technologies for the production of animal-free food solutions. This transaction allowed us to gain exposure to a fast-growing alternative food industry, an industry aligned with our purpose of helping food systems transition to carbon neutrality. We believe the transaction will unlock greater potential value from this asset and contribute to our consumer and market exposure. This concludes my prepared remarks, and I will now turn the call over to our CFO, Enrique López-Lecue, to discuss our fiscal third quarter financial results. Enrique?

Thanks Federico, good day to everyone and thanks for joining us today. Before entering into financial performance review, I would like to recall that during the quarter we completed the transfer of our listing from the NYSE American to the Nasdaq Global Select Market. We are grateful to NYSE for having been such a great host during more than two years since our initial listing back in March 2019. We are now thrilled about our new partnership with Nasdaq. It is an ideal fit for us as they represent some of the leading biotech, technology, and agtech companies in the world. This move also aligns with Biocetis' current ESG initiatives and Nasdaq's ESG platform and suite of products and services. Now getting to the financials, please turn to slide 10 for a review of their revenue performance during the quarter and on an LTM basis. Even when our fiscal third quarter is the slowest from a seasonal perspective, this year we had an outstanding performance with a historic high in revenues. Total comparable revenue rose by more than $9 million from $26 million in the third quarter of fiscal year 2020 to $35 million in the third quarter of the current fiscal year, a 35% increase. On a reported basis, the increase for the quarter was slightly above 40%, from $25.7 million to $36.2 million. Global nutrition expansion was behind the growth achieved during the quarter, characterized by the lack of planting activities across the market in which we operate. As we discussed in previous calls, to smooth down the effect of seasonality and have a good grasp of the mid-term performance of the business, we also keep a close eye on the trailing 12 months. The exceptional performance in a rather usually low-season quarter got us back on track with growth, leaving behind the slowdown we had seen in the second quarter. On an LTM basis, revenue as of March 2021 was $177 million, a 12% increase compared to the year-ago period, confirming the potential of our basement business to deliver attractive growth even ahead of HV4 impacting our top line. Please move on to slide 11 now for a breakdown in revenues per business segment. As I just explained, the $9.1 million growth for the quarter was delivered entirely by the crop nutrition segment that grew to $15.1 million in comparable revenues, and more specifically fully explained by a four times growth in micro-eat fertilizer sales. The strong performance in this particular product line during the quarter is the initial outcome of a shift in the commercial strategy to improve the attractiveness of the value proposition to farmers. we fundamentally believe that showing conviction in the technology and making the first move with a more aggressive pricing structure will allow us to achieve higher volumes at a faster pace with a higher use of our installed capacity which increased from 25 percent to 34 percent on a sequential basis we expect capture economies of scales that in turn will allow us to crystallize the level of gross margins that we have seen until now, which are very attractive compared to conventional fertilizers, but with a significantly bigger business line in terms of revenues and profits. The current momentum in grain commodity prices could not have been a better scenario to launch this new value proposition, as farmers are more inclined to spend dollars on fertilizing their fields. Margins for fertilizers remain fairly stable, with the overall crop nutrition segment dropping only 89 basis points versus the year-ago quarter, basically explained by significantly higher participation of fertilizers versus higher margin in uplands. Crop protection sales in the third quarter of fiscal 2021 were roughly flat compared to the year-ago quarter at $16.4 million. Average gross margin for the segment expanded by 148 basis points to 39.4%, a positive shift in the product mix, with a higher contribution to sales from adjuvants and lower sales of third-party products. For seed and integrated products, comparable revenues in the third quarter of fiscal 2021 were $3.5 million, slightly down from the year-ago quarter. Most but not all of the 96% seed treatment packs growth our French subsidiary had accomplished last year was retained, which explains the $400,000 decline. Margins for the segment remained fairly flat at 68.3%. Overall, we are very satisfied with growth during the quarter. It was achieved with an average margin expansion of 362 basis points, achieving a 50% average gross margin for the business. Now looking to the near future, similarly to the reorganizational process we pursued in the crop nutrition segment, which has already begun to show results, we are currently endeavoring initiatives to reignite profitable growth in our baseline, crop protection, and seed and integrated products business segments. We are optimistic about the near and mid-term effects of these strategy adjustments and expect them to positively impact our financial performance in the coming quarter and in the second half of the year, respectively. Moving on to slide 12 now, which shows the breakdown of gross profits per business segment. Following the increasing revenues and marketing expansion that we just discussed, Compatible gross profit rose by $5.5 million during the quarter, moving from $12 million in the third quarter of fiscal 2020 to $17.5 million during the third quarter of the current fiscal year, a 45.4% increase. Reported gross profit increased from $10.8 million to $15.3 million. Compatible gross profit for Crop protection was $6.5 million in the third quarter of fiscal 2021, slightly above gross profit of the previous fiscal year quarter, despite the slight drop in revenues. This was primarily due to higher participation of adjuvants in the mix in detriment of lower margin third-party products. Even integrated products contributed $2.4 million in comparable gross profits during the quarter, slightly down from the year-ago period, and in line with the revenue dynamics that I described in the previous slide, as margins remained flat. Finally, crop nutrition delivered $8.7 million in comparable gross profit during the third quarter of fiscal 2021, which represented almost half of the total comparable gross profits for the quarter. something unusual compared to past quarters in which crop nutrition represented on average no more than 20% to 25% of overall gross profits. Let's please move on to slides 13 and 14 for a review on EDAP performance for the quarter and for the last 12 months respectively. The $5.5 million increase in compatible gross profits versus the year-ago quarter was partially offset by IAS 29 adjustments, netting a $4.6 million increase in reported gross profits. This sharp increase in gross profits fully impacted on adjusted EBITDA, which totaled $6.9 million, a 163% increase versus the year-ago quarter that stood at $2.6 million. JV results were also a main contributor to adjusted EBITDA improvement with $1 million. As microlit fertilizers performance increased results from CinerTech, our fertilizers manufacturing JV, which is equity accounted for in the adjusted EBITDA line. A separate note on operating expenses, which totaled $11.7 million, up 17% from the year-ago quarter, The increase in SG&A expenses was primarily due to additional outsourced professional services partially upset by decreased travel expenses and lower distributions of share-based incentives. SG&A expenses down 659 basis points as a percentage of revenue, denoting continued operational leverage as SG&A grows at a slower pace than our gross profits. R&D expenses were also up in the quarter, explained by the development of wheat-oriented technologies, including the registration of HB4 wheat for production in the USA, which Federico previously mentioned. In slide 14, similarly to what I mentioned about revenues, we usually keep an eye on profitability over a period of 12 months to assess the performance of the business. The 12% growth in sales on an LTM basis versus the year-ago period delivered a solid 14% increase in adjusted EBITDA, growing from $40.6 million in the previous 12 months to March 2020, to $46.4 million over the 12-month period ending in March 31, 2021. Now, in breaking down contributions to that growth, even when IAS 29 adjustments significantly eroded an increase of $11.8 million in comparable gross profits, operational performance delivered almost $2.8 million in additional reported gross profits versus the year-ago LTM. That was further increased by a reduction in operating expenses and JVs performance. Finally, let's please turn to slide 15 to address our debt and cash position together with our performance on financial expenses. We continue to make good use of Resolactor's partnership with Argentina Credit Markets throughout the border as we completed a $26 million public offering of Series 5 corporate bonds in early March. 20% of these issuance corresponded to Class A, which had a one-year maturity and an annual coupon rate of 0.98%. And the remaining 80% was issued with a maturity of 36 months and an annual coupon rate of 5.5%. Processes are being used to support working capital needs, extended maturities, and to continue reducing our financing costs. Discussing previous calls, we have used the capital markets to replace inefficient sources of working capital, mainly factoring, with financial debt. Even when our total financial debt increased by $35.7 million from the third quarter of fiscal 2020, first left-hand column, to the third quarter of the current fiscal year, cash financial expenses decreased by $7.9 million from $20.6 million for the 12-month period prior to March 2020 to $12.7 million for the last 12 months as of March 31st, 2021. That is a 38% decrease in LTM financial expenses reflecting a significantly lower average cost of debt. Total net debt as of March 31st, 2021 was $134.2 million 2.89 times net debt to LPM adjusted EBITDA. The increase in the company's debt ratio compared to the prior fiscal year was primarily due to the aforementioned increase in total financial debt. Now, on a sequential basis, net debt to LPM adjusted EBITDA decreased from 3.05 times on December 31st, 2020, primarily due to the adjusted EBITDA growth during the third quarter. On the liquidity front, cash and cash equivalents, restricted short-term deposits, and other short-term investments represented approximately 58% of the current portion of debt, totaling slightly below $50 million. In addition to the strength of the SSS core business, we retain a solid liquidity position to continue serving the rollout of the HB4 wheat and soy during the upcoming quarters as the main growth priority for the company. That concludes the financial remarks we had prepared for today's call, so I will now turn it to Federico for concluding remarks or to go directly into any questions that you might have.